Hepatoprotective effects and mechanisms of Ixeris denticulate water extract on liver cirrhosis in experimental rat.
Bax
Bcl-2
Hepatoprotective
Ixeris denticulate
Liver cirrhosis
NF-κB p65
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
received:
03
09
2019
accepted:
19
05
2020
entrez:
7
6
2020
pubmed:
7
6
2020
medline:
2
12
2020
Statut:
epublish
Résumé
To explore the protective effect and mechanisms of Ixeris denticulate water extract (IDWE) in the development of liver cirrhosis in experimental rat. Sixty rats were randomly divided into five groups: control group, model group and IDWE (2, 4 and 8 g/kg) treatment groups. Alanine transferase (ALT), aspartate transaminase (AST), albumin (ALB), tumor necrosis factor-alpha (TNF-α), Interleukin (IL)-6 and IL-8 in serum and superoxide dismutase (SOD), malondialdehyde (MDA) in liver tissue were evaluated, respectively. The liver index, liver morphology and liver histopathological analysis were detected as a supportive data. The liver protein expression of Bcl-2 and Bax were assessed by western blot, and NF-κB p65 protein expression was determined by immunohistochemistry analysis. The result showed that a significantly decrease in the levels of serum AST, ALT and serum inflammatory factors TNF-α, IL-6 and IL-8 in IDWE-treated rats. The levels of serum ALB and SOD in liver tissue were markedly increased after IDWE treated, compared with model rats. Furthermore, IDWE-treated group also exhibited a down-regulated protein expression of NF-κB p65 and Bax, up-regulated Bcl-2 protein expression. IDWE could effectively alleviate the course of liver cirrhosis in rat model, which may be a potent hepatoprotective agent in clinical therapy in the future.
Sections du résumé
BACKGROUND
BACKGROUND
To explore the protective effect and mechanisms of Ixeris denticulate water extract (IDWE) in the development of liver cirrhosis in experimental rat.
METHODS
METHODS
Sixty rats were randomly divided into five groups: control group, model group and IDWE (2, 4 and 8 g/kg) treatment groups. Alanine transferase (ALT), aspartate transaminase (AST), albumin (ALB), tumor necrosis factor-alpha (TNF-α), Interleukin (IL)-6 and IL-8 in serum and superoxide dismutase (SOD), malondialdehyde (MDA) in liver tissue were evaluated, respectively. The liver index, liver morphology and liver histopathological analysis were detected as a supportive data. The liver protein expression of Bcl-2 and Bax were assessed by western blot, and NF-κB p65 protein expression was determined by immunohistochemistry analysis.
RESULTS
RESULTS
The result showed that a significantly decrease in the levels of serum AST, ALT and serum inflammatory factors TNF-α, IL-6 and IL-8 in IDWE-treated rats. The levels of serum ALB and SOD in liver tissue were markedly increased after IDWE treated, compared with model rats. Furthermore, IDWE-treated group also exhibited a down-regulated protein expression of NF-κB p65 and Bax, up-regulated Bcl-2 protein expression.
CONCLUSIONS
CONCLUSIONS
IDWE could effectively alleviate the course of liver cirrhosis in rat model, which may be a potent hepatoprotective agent in clinical therapy in the future.
Identifiants
pubmed: 32503634
doi: 10.1186/s12906-020-02957-w
pii: 10.1186/s12906-020-02957-w
pmc: PMC7275494
doi:
Substances chimiques
Biomarkers
0
Plant Extracts
0
Protective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175Références
Dig Liver Dis. 2019 Oct;51(10):1423-1429
pubmed: 31113738
Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):108-18
pubmed: 21293511
J Gastroenterol. 2016 Jul;51(7):629-50
pubmed: 27246107
Exp Mol Pathol. 2017 Oct;103(2):137-140
pubmed: 28818508
Phytochemistry. 1999 Jan;50(1):113-5
pubmed: 9891935
J Ethnopharmacol. 2011 Jul 14;136(3):428-35
pubmed: 20573566
Iran J Public Health. 2019 Mar;48(3):494-500
pubmed: 31223577
Clin J Gastroenterol. 2019 Oct;12(5):387-397
pubmed: 30980261
Ann Hepatol. 2019 Jan - Feb;18(1):48-57
pubmed: 31113608
PLoS One. 2016 Jun 23;11(6):e0157601
pubmed: 27336298
Chin Med J (Engl). 2015 Mar 5;128(5):620-5
pubmed: 25698193
Ter Arkh. 2019 Mar 18;91(2):73-81
pubmed: 31094175
Life Sci. 2019 Jun 1;226:91-97
pubmed: 30978348
J Biochem Mol Toxicol. 2015 Jun;29(6):288-97
pubmed: 25914167
Eur J Clin Pharmacol. 2019 Aug;75(8):1047-1058
pubmed: 31079169
Sci Rep. 2018 Jun 15;8(1):9163
pubmed: 29907790
Int Immunopharmacol. 2018 Jul;60:1-8
pubmed: 29702278
Ugeskr Laeger. 2014 Feb 17;176(4):
pubmed: 25095867
Evid Based Complement Alternat Med. 2015;2015:170792
pubmed: 26175792
Ann Hepatol. 2019 Jan - Feb;18(1):274-278
pubmed: 31113605
Biomed Pharmacother. 2017 Dec;96:1395-1402
pubmed: 29169724
Biomed Pharmacother. 2018 May;101:961-971
pubmed: 29635906
PLoS One. 2019 Jul 3;14(7):e0219219
pubmed: 31269063
Curr Drug Targets. 2016;17(15):1804-1817
pubmed: 27296314
Am J Pathol. 1994 Mar;144(3):460-5
pubmed: 8129031
Nat Prod Res. 2017 Jan;31(2):159-162
pubmed: 27553079
Aliment Pharmacol Ther. 2019 Jun;49(11):1421-1430
pubmed: 30957910
Food Chem Toxicol. 2019 Dec;134:110806
pubmed: 31521635
Dis Markers. 2018 Sep 2;2018:7936736
pubmed: 30245755
Cell Res. 2011 Jan;21(1):159-68
pubmed: 21187858
J Inflamm (Lond). 2012 May 04;9(1):16
pubmed: 22559721
Phytother Res. 2008 May;22(5):640-5
pubmed: 18350512
Front Pharmacol. 2019 May 31;10:601
pubmed: 31231215
Ter Arkh. 2019 Mar 18;91(2):67-72
pubmed: 31094174
Molecules. 2018 Aug 10;23(8):
pubmed: 30103395
Mol Pharmacol. 2018 Aug;94(2):834-841
pubmed: 29844231
J Inflamm (Lond). 2013 Oct 03;10(1):30
pubmed: 24090365
Ter Arkh. 2019 May 16;91(4):21-27
pubmed: 31094472
Molecules. 2017 May 30;22(6):
pubmed: 28555066